People: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

62.94USD
26 Mar 2015
Change (% chg)

-- (--)
Prev Close
$62.94
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,532,485
52-wk High
$75.17
52-wk Low
$38.49

Search Stocks

Anstice, David 

Mr. David W. Anstice is an Independent Director of Alkermes Plc. From October 2008 to September 16, 2011, he served on the Alkermes, Inc. board of directors. From 2006 until his retirement in 2008, he served as Executive Vice President of Merck, with responsibility for enterprise strategy and implementation. During two separate parts of this period he was acting President, Global Human Health and President of Merck's business in Japan. From 2003 to 2006, He served as President of Merck, with responsibility for Merck's Asia Pacific businesses. In his 34 years with Merck, he held a variety of positions including President, U.S. Human Health; President, Human Health, the Americas; President, U.S./Canada; and President, Human Health, Europe. He reported to the Merck CEO from 1994 until his retirement in 2008. Mr. Anstice is also Chairman and President of the board for the University of Sydney USA Foundation, Vice Chairman and a member of the board of the U.S. Studies Centre based at the University of Sydney, Australia, and a member of the board of the US Foundation of the University of the Valley of Guatemala, a member of the U.S. Advisory Council for the American Australian Association in New York, a director of CSL Limited, a global specialty biopharmaceutical company, a board member of the private company NeuClone Pty. Ltd, a cell line production company, and an Adjunct Professor at the University of Sydney Business School. Mr. Anstice's lengthy service with Merck, in combination with the breadth of his responsibilities while at Merck, provides us with experience in, and knowledge of, the global research-based pharmaceutical industry. Mr. Anstice's prior leadership positions in industry organizations, including as a board and executive committee member of BIO for approximately ten years and as Chairman of the National Pharmaceutical Council in 1997, augment his pharmaceutical management, organizational expertise and industry knowledge with knowledge of public policy issues involving pharmaceutical care.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Pops

8,696,650

Shane Cooke

3,912,100

James Frates

2,095,130

Gordon Pugh

1,965,720

Kathryn Biberstein

2,488,720

Rebecca Peterson

--
As Of  30 Mar 2014
Search Stocks